Tenvir 300 mg Tablets
Tenvir 300 mg Tablets is a trusted medication containing Tenofovir, designed for personal use under the guidance of a healthcare professional. Available for prescription-based international supply with discreet worldwide delivery.
- Active ingredient: Tenofovir Disoproxil Fumarate
- Strength: 300 mg
- Form: Tablet
- Indication: HIV-1 infection, Hepatitis B
- Manufacturer: Cipla Ltd.
Select quantity:
What is Tenofovir Disoproxil Fumarate?
How Does It Work?
TDF enters HIV-infected CD4+ T cells and macrophages and is converted to its active form, tenofovir diphosphate (TFV-DP).
TFV-DP competes with the natural substrate dATP, incorporating into the viral DNA chain and causing premature termination of reverse transcription.
Without functional reverse transcriptase, HIV cannot replicate. Consistent dosing maintains undetectable viral loads in most patients.
How to Use
Take exactly as prescribed. Your prescriber's instructions replace the general guidance above.
Side Effects & Precautions
- Nausea
- Diarrhoea
- Headache
- Dizziness
- Fatigue
- Lactic acidosis (rare but serious)
- Kidney impairment — monitor renal function
- Decreased bone density with long-term use
- Severe hepatomegaly with steatosis
- Severe renal impairment (CrCl <30 mL/min) without dose adjustment
- Known hypersensitivity to tenofovir
Generic vs Brand
Hari Ramalingam is a licensed clinical pharmacist with 14 years of experience. He holds a B.Pharm from Dr. M.G.R. Medical University. At OnlineMeds, he reviews medicine and health content to help ensure it is accurate, evidence-based, and easy to understand.
Storage & Handling
Why Buy From Us
Sourced directly from licensed pharmaceutical manufacturers.
Sourced from licensed manufacturers through regulated supply channels.
Discreet shipping to UK, US, AU, EU and beyond.
Regulated and compliant with international pharmacy standards.
Frequently Asked Questions
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with nucleoside analogues.
Severe acute exacerbations of Hepatitis B have been reported in HBV-infected patients who discontinue TDF.
Drug Interactions
| Drug / Substance | Effect | Action |
|---|---|---|
| Didanosine (ddI) | Increased ddI exposure — risk of pancreatitis | Avoid combination |
| Atazanavir | TDF increases atazanavir exposure | Boost with ritonavir; monitor |
| NSAIDs / nephrotoxic drugs | Additive renal toxicity | Monitor renal function closely |
Approved Indications
- HIV-1 infection (adults and paediatrics ≥2 years) FDA / EMA
- Chronic Hepatitis B in adults FDA / EMA
- Pre-exposure prophylaxis (PrEP) for HIV-1 FDA